- Report
- March 2024
- 145 Pages
Global
From €3763EUR$3,899USD£3,228GBP
- Report
- August 2022
- 117 Pages
Global
From €4343EUR$4,500USD£3,726GBP
- Report
- April 2024
- 50 Pages
Global
From €2558EUR$2,650USD£2,194GBP
- Report
- September 2019
Global
From €5183EUR$5,370USD£4,446GBP
- Report
- January 2022
- 137 Pages
Global
From €4343EUR$4,500USD£3,726GBP
- Book
- July 2009
- 1116 Pages
Retigabine is a drug used to treat epilepsy, a neurological disorder characterized by recurrent seizures. It is a potassium channel opener, meaning it works by increasing the activity of potassium channels in the brain, which helps to reduce the frequency of seizures. Retigabine is classified as an antiepileptic drug, and is part of a larger class of drugs known as Central Nervous System (CNS) drugs. These drugs are used to treat a variety of neurological disorders, including epilepsy, Parkinson's disease, and Alzheimer's disease.
Retigabine is approved for use in the United States, Europe, and other countries. It is available in both oral and intravenous formulations. The drug is typically prescribed as an add-on therapy for patients who have not responded to other antiepileptic drugs.
Some companies in the Retigabine market include GlaxoSmithKline, Eisai, and Lundbeck. Show Less Read more